Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas

BACKGROUND. Mibefradil (MIB), previously approved for treatment of hypertension, is a selective T-type calcium channel blocker with preclinical activity in high-grade gliomas (HGGs). To exploit its presumed mechanism of impacting cell cycle activity (G1 arrest), we designed a phase I study to determ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Holdhoff, Matthias, Ye, Xiaobu, Supko, Jeffrey G., Nabors, Louis B., Desai, Arati S., Walbert, Tobias, Lesser, Glenn J., Read, William L., Lieberman, Frank S., Lodge, Martin A., Leal, Jeffrey, Fisher, Joy D., Desideri, Serena, Grossman, Stuart A., Wahl, Richard L., Schiff, David
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464434/
https://ncbi.nlm.nih.gov/pubmed/28371832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados